先说结论
If you mostly use chat-style AI and keep seeing headlines like "A near-autonomous AI chemist improves a challenging reaction in medicinal chemistry," the easy mistake is to think: AI replaces chemists next.
That is the wrong bottleneck. AI is more likely to kill blind screening first, meaning the 50-60 low-signal trial reactions teams run just to find the 5-10 that matter, than medicinal chemists.
Why this matters even outside a lab: if you track AI by the most human-looking demo, you waste time, budget, and attention on the wrong thing. The first expensive loop getting compressed is not chemical judgment. It is low-information trial and error.
为什么这次值得看
The scene here is familiar. You see an "AI chemist" headline, almost scroll past, then wonder if you are already behind. The useful question is not "Can it think like a chemist?
" It is "Which part of the workflow stops needing blind shots?"
In the 2026 Nature case, the system was applied to one unreported nickel-catalyzed coupling. It screened only 4-6 ligands, the catalyst's helper molecules, per round, reached the near-optimal region in 4 rounds and 26 experiments, and improved one difficult starting material from 74% to 85% selectivity for the desired mirror-image product [S001].
UCLA researchers described the same economic shift more bluntly: work that often took 50-60 reactions could drop to 5-10, saving weeks or months and reducing material cost [S002].
关键证据
That does not mean every medicinal chemistry route now works this way. It does support a narrower and more useful takeaway: the first thing AI kills is blind screening, not the medicinal chemist.
The way to judge an AI update is not by how many features it lists, but by whether it changes your next decision.
If you lead R&D, process, or platform work, ask one question: where are you still burning 50-60 blind shots to find the 5-10 that matter?
Share this with the person who is still reading AI as a talent replacement story instead of a trial-and-error compression story.
适合谁 / 下一步怎么用
最后落到动作:share
share。